P2D Bioscience Lead ADHD Drug Demonstrates Efficacy in Preclinical Testing
CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - 04/12/11) - P2D Bioscience (P2D, Inc.), a pharmaceutical development company, today announced that its lead Attention Deficit/Hyperactivity Disorder (ADHD) stimulant drug, PD2005, demonstrated efficacy in treating the core symptoms of ADHD in preclinical ADHD models. The independently conducted studies were funded by a grant from the National ...
Read more on
订阅：
博文评论 (Atom)
没有评论:
发表评论